Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Novartis, Cota Healthcare Ink Precision Medicine Collaboration Deal

Wednesday, March 29, 2017   (0 Comments)
Share |

The multi-year research agreement will see the pharmaceutical company putting Cota's analytics platform to work for improved breast cancer treatment outcomes.


Expanding on a partnership first announced in 2016, Cota Healthcare and Novartis Pharmaceuticals Corporation have signed a multi-year agreement to work together toward improved clinical and cost outcomes for breast cancer patients.

Novartis will use Cota's cloud-based platform for evidence-based medicine to speed the development of therapies for breast cancer, using analytics and data visualization tools to identify the patients who would most benefit.

Cota's technology runs on its patented Cota Nodal Address system, which the company bills as a digital classification methodology than can stratify patients based on various personal and clinical factors. Patients with the same CNA can be considered "medically identical," according to Cota, and could benefit from similar treatments.

"Data and insight that comes directly from patient records – real-world evidence – is transforming how pharmaceutical and life science companies develop more precise, targeted therapies," said John Hervey, CEO of Cota, in a statement.

"Analyzing this data using CNAs is a critical factor in enabling healthcare companies to develop and target therapies that increase outcomes and lower the total cost of care," said Andrew Pecora, MD, Cota's founder and executive chairman.

View complete article here.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal